Guardant Health (GH) Earns “Outperform” Rating from William Blair
Other research analysts have also issued reports about the company. Bank of America reiterated a neutral rating and issued a $60.00 target price (up from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. JPMorgan Chase & Co. lifted their target price on Guardant Health from $42.00 to $85.00 and gave the company an overweight rating in a report on Wednesday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Guardant Health has a consensus rating of Buy and an average price target of $72.50.
GH opened at $97.98 on Wednesday. Guardant Health has a 52 week low of $27.04 and a 52 week high of $106.58. The firm has a market cap of $8.48 billion and a PE ratio of -34.99.
In other Guardant Health news, major shareholder Vision Fund (Aiv M1) Softbank purchased 2,033,990 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was bought at an average cost of $9.83 per share, with a total value of $19,994,121.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
A number of hedge funds and other institutional investors have recently made changes to their positions in GH. Temasek Holdings Private Ltd purchased a new stake in Guardant Health during the 4th quarter worth about $60,633,000. Orbimed Advisors LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $57,681,000. BlackRock Inc. acquired a new stake in shares of Guardant Health during the fourth quarter worth about $41,894,000. Jennison Associates LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $31,700,000. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $20,024,000. 69.54% of the stock is owned by institutional investors.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Featured Article: Gross Domestic Product (GDP)
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.